Biomarin Pharmaceutical INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$14Mgeneral payments (2019-2025)
$176Kresearch payments (2019-2025)
4,975clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Willard Dere | Salt Lake City, UT | Internal Medicine | $3,325,522.00 |
| Dennis Slamon | Los Angeles, CA | Hematology & Oncology | $3,016,561.79 |
| Barbara Burton | Chicago, IL | Clinical Genetics (M.D.) | $348,038.02 |
| Cathleen Raggio | Uniondale, NY | Pediatric Orthopaedic Surgery | $262,198.53 |
| Philippe Backeljauw | Cincinnati, OH | Pediatric Endocrinology | $245,196.02 |
| Julie Hoover-Fong | Baltimore, MD | Clinical Genetics (M.D.) | $215,436.36 |
| Cary Harding | Portland, OR | Clinical Genetics (M.D.) | $181,670.46 |
| Hope Northrup | Houston, TX | Clinical Genetics (M.D.) | $167,586.91 |
| Ronald Crystal | New York, NY | Pulmonary Disease | $166,000.00 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $165,605.86 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.